Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

DHA / Omega-3

The Fetal Brain and Preterm-Birth Fatty Acid

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

70 human trials, about 4 studies, 2018 Cochrane: 70 RCTs, ~10,304 participants. The written rationale for this grade is still being prepared.

FDA
Regulated as a dietary supplement; no formal RDA, but expert intake targets exist
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

DHA is generally well tolerated; fish-oil sources can cause a fishy aftertaste or mild digestive upset, and algal DHA is a plant-based option for those who avoid fish. The more important nuance is that more is not universally better. A higher 1,000 mg dose outperformed 200 mg mainly in women who began pregnancy with low DHA, while the ORIP trial found no overall benefit in an already-replete group and an exploratory analysis noted more early preterm births among women who started with high omega-3 status and were then supplemented. Because those findings mean dose and timing depend on individual status, decisions about supplementation are best made with an obstetric clinician or midwife rather than from a label. When choosing seafood as a source, favoring lower-mercury fish helps limit methylmercury exposure, an issue covered in the fish and mercury entry.

DHA is a long-chain omega-3 fatty acid and a major structural material of the fetal brain and retina, with the fastest accumulation in the third trimester. The firmest trial evidence is not about intelligence but about timing of birth: the 2018 Cochrane review of 70 randomized trials found high-quality evidence that omega-3 in pregnancy lowered preterm birth by about 11 percent and early preterm birth by about 42 percent. That headline comes with a real qualifier, because the largest single trial, ORIP, found no effect in women who already had good omega-3 status, and the benefit in later trials clustered in women who started low. Expert guidance from the NIH Office of Dietary Supplements and framing from ACOG now points to at least 250 mg per day of DHA plus EPA for women of reproductive age and an extra 100 to 200 mg of DHA in pregnancy, roughly the amount in 8 to 12 ounces of lower-mercury seafood per week. Most pregnant women in the US eat far less than that.

A fatty acid that builds the fetal brain and eye and, in good trials, lowers the risk of preterm birth, with a real twist about who actually benefits.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Contributing to fetal brain and retinal structure, especially during third-trimester growth
  • Associated with lower risk of preterm and early preterm birth, most clearly in women who begin pregnancy with low omega-3 status
  • Helping women reach expert intake targets when seafood consumption falls short
  • Maintaining maternal omega-3 status through lactation

What people get wrong

  • Often saidEvery pregnant woman should take a high-dose 1,000 mg DHA supplement.

    ActuallyThe higher dose helped most clearly in women who started pregnancy with low DHA. In ADORE, early preterm birth fell to 2.0 percent on 1,000 mg versus 4.1 percent on 200 mg among low-status women, while high-status women saw no dose benefit (1.4 vs 1.1 percent). An exploratory analysis of ORIP even flagged more early preterm births among already-replete women who were supplemented, so benefit appears tied to baseline status rather than to a bigger bottle.

  • Often saidPrenatal DHA is mainly about making the baby smarter.

    ActuallyThe strongest, highest-quality trial evidence is for reducing preterm birth, not for raising childhood IQ. The 2018 Cochrane child-outcome data showed very few differences in cognition, and the NIH Office of Dietary Supplements states that randomized trials have not shown consistent benefits of maternal EPA or DHA on infant cognition or visual development. DHA is structurally important to the developing brain, but the neurodevelopment claim is weaker than the birth-timing one.

  • Often saidMore omega-3 in pregnancy is always better.

    ActuallyThe largest trial, ORIP, gave 900 mg of n-3 daily to a mostly omega-3-replete population and found no reduction in early preterm birth (2.2 versus 2.0 percent). Cochrane also noted a probable increase in pregnancies going past 42 weeks with supplementation. The signal points to correcting a shortfall, not to loading a woman who already has adequate status.

Who profits, and who pushes back

  • NIH Office of Dietary Supplements

    championsNIH (2025 pregnancy guidance)

    Long-chain omega-3 supplements, particularly DHA, have been shown to reduce the risk of preterm and early preterm birth; women should consume at least 250 mg/day DHA plus EPA, with an additional 100 to 200 mg/day of DHA during pregnancy.

  • 2018 Cochrane Review authors

    championsSystematic review, 70 RCTs

    High-quality evidence shows omega-3 supplementation reduced preterm birth before 37 weeks by about 11% and early preterm birth before 34 weeks by about 42%.

  • Dr. Susan Carlson & ADORE investigators

    endorsesUniversity of Kansas; algal-DHA dose trial

    A 1,000 mg algal DHA dose was superior to 200 mg, reducing preterm birth by about 25%, and reduced early preterm birth by about 48% in women who entered pregnancy with low DHA status.

  • ACOG & FIGO

    caveatsObstetric authorities

    Pregnant people should eat 8 to 12 ounces of low-mercury seafood per week; these bodies recommend seafood for general nutrition but stop short of naming DHA as a preterm-birth intervention.

  • ORIP trial investigators

    mixedLarge Australian RCT

    Among women who began pregnancy with high DHA status, supplementation was paradoxically associated with a higher rate of early preterm birth, suggesting baseline status matters and universal high-dosing may not benefit everyone.

Where the research comes from

Most of the published research on this comes from one place. 80% of it is from Below DHA target. Findings that no unrelated group has reproduced are weaker than the study count makes them look.

Share of published research by country of origin.
PlaceShare of published research
Below DHA target80%
At or above20%

Research published from: Global.

How we got here

The thread starts in the North Atlantic and the Arctic rather than in a laboratory. In the 1970s the Danish researchers Hans Olaf Bang and Jorn Dyerberg studied Greenland Inuit, whose marine-fat diet paired with a low rate of coronary disease, and traced the effect to omega-3 fatty acids, publishing first in the Lancet in 1971. The pregnancy link came from the Faroe Islands, where the Danish epidemiologist Sjurdur Olsen noticed in the mid-1980s that Faroese women, heavy fish eaters, carried pregnancies longer and delivered heavier babies than women in Denmark. Olsen's 1992 Faroese fish-oil trial extended gestation by roughly four days, seeding decades of randomized work. Through the 2010s those trials accumulated into the 2018 Cochrane review, which established the preterm-birth benefit at high quality. Later trials, ADORE and ORIP, then complicated the story by showing that dose and a woman's starting omega-3 status shape who actually benefits.

  1. 1971Bang and Dyerberg publish their first Lancet work linking Greenland Inuit marine-fat diets to low heart-disease rates
  2. 1980sOlsen observes longer gestation and higher birthweight among fish-eating Faroe Islanders versus mainland Danes
  3. 1992Olsen's Faroese randomized fish-oil trial reports gestation extended by about four days
  4. 2018Cochrane review (Middleton, 70 RCTs, 19,927 women) grades reduced preterm and early preterm birth as high-quality evidence
  5. 2019ORIP trial (NEJM, 5,486 pregnancies) finds no overall effect on early preterm birth in a largely replete population
  6. 2021ADORE trial shows 1,000 mg DHA outperforms 200 mg mainly in women who begin pregnancy with low DHA
  7. 2025NIH Office of Dietary Supplements updates its fact sheets to link omega-3 DHA with reduced preterm-birth risk

At a glance

Baseline target
≥250 mg/day DHA+EPA
Added in pregnancy
100-200 mg DHA
Preterm-birth drop
~11% (Cochrane)
Early preterm drop
~42% (Cochrane)

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about DHA / Omega-3. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources